# Mitra RxDx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mitra-rxdx

- Industry: Healthcare IT
- Headquarters: Woburn, US
- Website: www.mitrabiotech.com
- Total disclosed funding: $67M
- Latest round: Series C (Jul 12, 2018)
- Investors on record: 6

## About

Mitra RxDx, Inc. is a biotechnology firm specializing in innovative digital health solutions aimed at improving patient diagnosis and treatment pathways through advanced data analysis and technology integration.Founded in 2010 and headquartered in Woburn, US, Mitra RxDx, Inc. focuses on digital health solutions that enhance patient care. The company has not undergone any major pivots in its business operations and does not have any subsidiaries. In July 2018, the company raised USD 40.00 mn in a Series C funding round led by Northpond Ventures, with participation from Accel, RA Capital, Sands Capital Alternatives, and Sequoia Capital. This round marked the completion of their total fundraising amount of USD 40.00 mn across 4 deals.Mitra RxDx, Inc. specializes in innovative digital solutions aimed at enhancing patient diagnosis and treatment. Their offerings include advanced analytics platforms that enable healthcare providers to better understand patient data, improve diagnostic accuracy, and optimize treatment plans. The services are particularly valuable for healthcare institutions looking to leverage technology for improved patient outcomes, and are marketed primarily in North America, Europe, and specific regions in Asia.The company's revenue model is based on a subscription framework, allowing healthcare providers to access their analytical platforms for a recurring fee. Clients can select from multiple pricing plans tailored to their needs, with options for additional features and support services. This direct-to-consumer approach fosters engagement and retention, ensuring a steady revenue stream from healthcare organizations utilizing their technology to enhance patient care.Mitra RxDx, Inc. plans to leverage the recent USD 40.00 mn from their Series C funding to expand its product offerings and enter new markets. They are currently developing new analytical tools aimed at further enhancing patient care and diagnosing capabilities, with expected releases in late 2023. Additionally, the company is targeting expansion into European and Asian markets by mid-2024 to broaden its reach and impact in the digital health sector.

## Funding rounds

- Series C, Jul 12, 2018, $40M — Accel, Hong Shan, RA Capital Management, Sands Capital Alternatives, Northpond Ventures
- Series B, Aug 29, 2016, $27M — Accel, Hong Shan, Tata Capital, RA Capital Management, Sands Capital Alternatives

## Investors

- Accel (https://capitalatlas.ai/funds/accel) — Series B, Series C
- Hong Shan — Series B, Series C
- Tata Capital (https://capitalatlas.ai/funds/tata-capital) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series B, Series C
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series C